STARTVAC

Selected form

Inactivated Vaccine For Cattle

Method of action: Immunologicals For Bovidae

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of STARTVAC

Property	Description
Active Ingredients	Inactivated E. coli J5, Inactivated S. aureus (CP8) strain SP 140
Form	Emulsion for Injection
Pharmacological Class	Immunologicals (Inactivated Bacterial Vaccine)
Common Use	Herd immunisation to reduce the incidence and severity of mastitis symptoms in cattle
Origin	Biological (Bacterial)

What Type of Medicine is STARTVAC?

STARTVAC is a veterinary medicinal product explicitly classified as an Immunological agent, specifically an inactivated bacterial vaccine intended for use in healthy cows and heifers in dairy cattle herds. The design is polyvalent, a defining characteristic that provides protection against two distinct major bacterial causes of udder health issues in a single preparation. This preventative strategy is clinically recognized for contributing to comprehensive health management programs.

Composition and Pharmaceutical Form

The composition features two primary active ingredients: inactivated Escherichia coli J5 and the specific inactivated Staphylococcus aureus (CP8) strain SP 140. This S. aureus strain is essential because it is engineered to express the Slime Associated Antigenic Complex (SAAC), a crucial component for generating targeted immunity. The product is supplied as an emulsion for injection, a pharmaceutical form that includes liquid paraffin serving as an adjuvant. This combination of an oil-based adjuvant with the parenteral administration route is designed to ensure a slow, sustained release of antigens.

General Purpose and Immunological Benefit

The general purpose is to contribute to udder health control programs by generating protective active immunity against the two major bacterial groups: Staphylococcus aureus and coliforms. The vaccine's role is to help reduce the overall disease burden within the herd. A typical use scenario involves administering the vaccine as part of a scheduled herd immunisation program, where it helps reduce the incidence and lessen the severity of clinical signs associated with mastitis caused by S. aureus, coliforms, and coagulase-negative staphylococci.

What side effects are possible with STARTVAC?

The official safety profile for the inactivated bacterial vaccine STARTVAC is documented according to regulatory standards, organizing potential adverse effects by frequency and the body system affected. This information is derived exclusively from authoritative government regulatory sources.

Classification of Adverse Reactions

The majority of documented post-administration safety observations are classified as Common, affecting more than 1 but less than 10 in 100 treated animals. Reactions are primarily categorized under General disorders and administration site conditions.

Common Reactions include a transient local reaction at the injection site, typically manifesting as a nodule or swelling. An increase in body temperature (hyperthermia) is also common, typically appearing within a few hours and resolving within 24 to 48 hours.
Uncommon Reactions (affecting up to 1 in 100 treated animals) include a transient drop in milk yield, which falls under Production Disorders and is noted in lactating cows.
Rare Reactions (affecting up to 1 in 10,000 treated animals) involve anaphylactic-type reactions. These are described as severe systemic hypersensitivity reactions and represent the most serious adverse event documented in regulatory texts.

Safety Restrictions and Contextual Notes

Official labeling defines several high-level constraints. The vaccine is indicated for use only in healthy cows and heifers. This safety restriction limits its use to animals not currently suffering from disease or high stress. Furthermore, regulatory documentation explicitly states that no information is available regarding the safety or effectiveness of this vaccine when used concurrently with any other medicinal product.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information on STARTVAC overdose and emergency action is based strictly on governmental regulatory documentation and pertains to the target species (cattle) and accidental human exposure.

Documented Overdose Manifestations

In cattle, administration of a double dose of STARTVAC was observed to cause no adverse reactions other than those already known for the standard regimen. The documented manifestations are limited to slight to moderate transient local reactions, such as swelling and pain at the inoculation site, and a transient increase in body temperature (fever).

However, the product's regulatory profile highlights the risk of anaphylactic-type reactions in some sensitive animals, which might be life-threatening. These reactions necessitate immediate action.

Required Emergency Actions and Urgent Medical Help

Situation	Required Action (As Labeled)
Cattle Anaphylaxis	Appropriate and rapid symptomatic treatment should be administered if life-threatening anaphylactic-type reactions occur.
Accidental Human Injection	Seek prompt medical advice immediately, even if only a very small amount is injected. Expert, prompt, surgical attention is required.

Accidental injection in humans, due to the mineral oil content, may cause severe pain and swelling and carries the risk of ischaemic necrosis or potential loss of the affected finger if immediate medical care is not obtained.

Therapeutic Uses of STARTVAC

What STARTVAC Treats: Main Uses and Benefits

STARTVAC is commonly used within dairy herd health management programs to support the mitigation of bacterial udder infections. Its use is considered relevant in dairy cattle herds with recurring mastitis problems and is established in practice. The vaccine is relevant for easing symptoms related to inflammatory states, particularly those associated with chronic subclinical mastitis and acute clinical mastitis.

It is applied across domains where additional symptomatic support is needed and is considered relevant in contexts involving infectious processes caused by coliforms (like E. coli), Staphylococci (including S. aureus), and coagulase-negative staphylococci (CNS). The use may assist with easing the symptom burden associated with new infectious episodes, and supports the management of the severity of acute, observable clinical signs.

“The product is commonly used across conditions presenting with acute episodes and relevant in conditions characterized by periods of heightened symptoms.”

This application is common in scenarios where additional management of discomfort is required, such as during phases of temporary physiological imbalance, ultimately helping to contribute to easing the overall symptom load within the herd.

Quick Fact: Supportive Role
Symptom Focus	Helps manage symptom clusters that may become intense or disruptive due to key bacterial pathogens like S. aureus and E. coli group infections.
Clinical Context	Relevant for easing symptoms in herds with recurring mastitis problems and subclinical disease indicators.

Regulatory References

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Eligibility and Restrictions for Use

Who can and cannot use STARTVAC?

The eligibility profile for STARTVAC is strictly determined by official regulatory documents that define the permitted population and any conditional requirements for use.

Eligibility Classification	Official Regulatory Status
Contraindications	None are listed in the official regulatory documentation.
Target Species	Cows (mature female cattle) and Heifers (young female cattle).
Use during Pregnancy	Permitted.
Use during Lactation	Permitted.

Population-Specific Restrictions

The authorized use of this product is conditional, as the official label specifies mandatory health and contextual requirements for the eligible population.

The vaccine is explicitly authorized only for healthy animals; this classification means that animals currently experiencing systemic illness or acute sickness are excluded from use. Both mature cows and younger heifers are confirmed as eligible age groups. Furthermore, the licensed indication restricts application to animals belonging to dairy cattle herds with recurring mastitis problems, establishing a mandatory precondition on the environment and history of the herd. Species other than cattle are not established as eligible populations under the official label.

What should I know about interactions with other medicines?

STARTVAC Interactions with other medicines and products

The regulatory profile for STARTVAC is strictly defined by administrative constraints and the documented status of co-administration data, rather than by specific pharmacokinetic (PK) or pharmacodynamic (PD) interactions.

Interaction Category	Official Regulatory Status
Physical Incompatibility	Mixing is prohibited with any other veterinary medicinal product.
Sequential Use Data	No information is available on the safety and efficacy of the vaccine when used before or after any other veterinary medicinal product.
Metabolic Interactions	None documented. The official label does not specify interactions related to CYP enzymes or drug transporters.
Food or Supplements	None documented. The label includes no restrictions regarding food, alcohol, or herbal supplements.

Official Interaction Constraints

The official documentation establishes two core constraints related to use with other substances:

Prohibition on Mixing: Due to documented physical incompatibility, this product must not be mixed with any other veterinary medicinal product prior to administration. This is a major regulatory restriction on co-preparation.
Sequential Administration Advisory: Given the explicit absence of safety and efficacy data for sequential use, the decision to administer STARTVAC before or after any other product requires a case by case basis assessment, as advised in the official summary. No specific timing separation rules are mandated.

The regulatory profile does not identify any substances that formally modify the exposure or clearance of STARTVAC, nor does it list any specific medicines or substance classes as formally contraindicated. The final interaction structure is focused solely on constraints related to co-preparation and the status of concurrent use data, as defined by the European Medicines Agency.

Mechanism of Action

STARTVAC functions as an inducer of antibody production, primarily targeting key bacterial surface antigens and associated virulence factors. The mechanism initiates upon interaction with Toll-like receptor 4 (TLR4), situated on the surface of antigen-presenting cells (APCs). This engagement triggers an intracellular signaling cascade, leading to the rapid and specific activation of the adaptive immune system. The consequent cellular proliferation and differentiation result in the generation of antigen-specific plasma cells and memory B cells. The resultant circulating antibodies bind to the targeted bacterial components, leading to opsonization and phagocytosis. This downstream cascade culminates in a system-level physiological consequence: a decreased pathogen presence within the host environment.

Dosage and Administration Information

How to use STARTVAC

The usage of STARTVAC is structured around a specific, time-dependent vaccination schedule tied to the reproductive cycle of dairy cattle.

Administration and Dosage Protocol

The product is an emulsion for injection and must be administered exclusively via the intramuscular route. The prescribed administration site is a deep injection into the neck muscles. Each dose consists of 2 ml and is intended only for use in healthy cows and heifers as part of a scheduled herd immunisation program. The vaccine is approved for use during pregnancy and lactation, providing critical context for its administration.

The Three-Injection Primary Schedule

STARTVAC requires a primary course of three separate injections, a regimen that must be fully repeated with each subsequent gestation. The timing of these doses is precisely defined relative to the expected calving date:

Dose	Timing Relative to Parturition (Calving)
First Injection	45 days before the expected parturition date.
Second Injection	10 days before the expected parturition date (35 days after the first injection).
Third Injection (Booster)	52 days after the parturition date (62 days after the second injection).

Preparation and Procedural Rules

Prior to drawing the 2 ml dose, the emulsion must be allowed to reach a temperature between 15°C and 25°C and shaken well to ensure uniformity. For optimal site management, the injections should be administered on alternate sides of the neck. The product carries a Zero-day withdrawal period for both milk and meat.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early-Stage Clinical Trials

Focus: The initial stages of research investigated how the drug was processed by the body and its initial safety profile in healthy volunteers.

Early trials examined whether the drug was associated with a change in joint inflammation. The results informed the design of later studies regarding potential dose levels.
Studies evaluated whether Drug X was associated with a reduction in reported pain for patients with moderate to severe illness. These exploratory results prompted further investigation in larger-scale trials.
The use of Drug X has been studied under the supervision of a specialist, which reflects the context of clinical trials.

Phase 3 Randomized Controlled Trials (RCTs)

Primary Endpoint Investigation:

Research has explored whether Drug X is associated with an improvement in symptoms and a reduction in flare-ups when compared to a placebo. The primary outcome measure was a specific percentage change on a standardized disease activity scale.
A study compared Drug X to Drug Y to examine clinical outcomes. The research collected data on rates of adverse events and patient-reported quality of life.
The formulation was investigated for its potential association with rapid changes and for its role in future disease progression. Evidence regarding long-term outcomes from this specific trial remains limited beyond the initial 12-month evaluation.

Long-Term Follow-Up Data

Long-Term Research Goals:

Research has investigated the potential role of this combination treatment and its long-term use in a subset of participants who completed the core Phase 3 trials.
The trials monitored participants for up to five years to explore the frequency and types of adverse events over an extended period.
Studies evaluated whether continuous use of Drug X was associated with sustained differences in disease activity scores, observing data annually.

Frequently Asked Questions (FAQ)

Common questions about STARTVAC (FAQ)

Q: Can I use the vaccine in a cow that is already sick?

According to official product information, STARTVAC is indicated exclusively for use in healthy cows and heifers. The product information states the vaccine is not authorized for use in animals currently experiencing systemic illness or acute sickness.

Q: What should I do if the vaccine has been frozen?

The product label explicitly states, 'Do not freeze.' Freezing can potentially affect the stability and effectiveness of the emulsion. If a product is accidentally frozen, standard practice is to not use it as its effectiveness may be compromised.

Q: What is the shelf life of STARTVAC after I open the bottle?

Once the container is opened, the product has a restricted shelf life. The official regulatory documents state the product should be used within a 10-hour period after opening, provided the opened container is stored at a temperature between +15 C and +25 C.

Q: How long does the local reaction or swelling at the injection site last?

Official documentation reports that the slight to moderate transient local reactions, such as swelling at the injection site, typically disappear spontaneously within one to two weeks at most. The documentation indicates that any associated pain at the site typically subsides in a maximum of four days.

Q: Can STARTVAC be mixed with a vitamin injection before administering?

No. The regulatory information strictly prohibits mixing STARTVAC with any other veterinary medicinal product prior to its administration. This restriction is based on documented physical incompatibility and official regulatory constraints.

Q: Where can a farmer legally buy STARTVAC?

Official regulatory texts classify STARTVAC as a veterinary medicinal product subject to prescription. This means the product is not available for general sale and is intended to be obtained through authorized channels, such as a veterinarian.

Q: What is the maximum volume of swelling at the injection site that is considered normal?

Official safety data indicates that the swelling observed is typically slight to moderate, with a size of up to 5, cm^2 on average being reported within the expected range of a common local reaction.

How should STARTVAC be stored and disposed of?

The storage and disposal of STARTVAC (Emulsion for injection) must adhere strictly to officially documented regulatory requirements to ensure product stability and proper handling.

️ Storage Conditions

STARTVAC must be stored and transported refrigerated within the mandatory temperature range of 2 °C to 8 °C. The product must not be frozen and must be actively protected from light.